Lead Investigator: Linsen Ye, The Third Affiliated Hospital, Sun Yat-Sen University
Title of Proposal Research: Effect of liver lipid deposition on the treatment of atezolizumab plus bevacizumab: a retrospective study based on the IMBrave150
Vivli Data Request: 10313
Funding Source: National Natural Science Foundation of China, Grant ID 82103448
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Chronic hepatitis B is a long-lasting infection of the liver caused by the hepatitis B virus. It can lead to serious liver problems, including liver cancer. Liver cancer is a type of cancer that starts in the cells of the liver and is difficult to treat if not caught early. Another related condition is fatty liver disease, where fat builds up in the liver, making it hard for the organ to function properly. These conditions are important because many people around the world are affected by them, leading to health issues that impact their daily lives and well-being.
This research will look at the effects of two medications called Atezolizumab (commonly known as “T”) and Bevacizumab (“a”) when given together to treat liver cancer in patients who also have fatty liver disease. Atezolizumab workS by helping the immune system to recognize and kill cancer cells, whereas bevacizumab works by stopping the cancer from growing blood vessels, so it is starved and can’t grow.The combination of these two medications is known as “T + a.” We want to understand if the presence of fat in the liver changes how well these treatments work.
Understanding how liver fat affects treatment outcomes can help doctors provide better care for patients with liver cancer, especially those with chronic hepatitis B and fatty liver disease. If we learn that fat in the liver impacts treatment effectiveness, we may need to adjust our approach to using these medications for better results. This research could lead to improved treatment options for many people suffering from these liver conditions, potentially saving lives and improving quality of life.
This study aims to help healthcare providers understand the connection between liver fat and treatment success in liver cancer patients. By doing so, we hope to enhance medical knowledge and improve patient care for those affected by chronic hepatitis B, liver cancer, and fatty liver disease.
Requested Studies:
A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Data Contributor: Roche
Study ID: NCT03434379
Sponsor ID: YO40245